Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial)
| Autor: | Olivier Dupuis, Pascal Piedbois, T. Aziza, Rosine Guimbaud, P. Valleur, Daniel Cherqui, A. Piolot, A. C. Braud, G. Ganem, C. Tayar, H. Kobeiter, J. Auroux, Roland Bugat, E. Haddad, Laurent Zelek, P. L. Fagniez, Marc Buyse |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Neutropenia Colorectal cancer medicine.drug_class medicine.medical_treatment Pirarubicin Leucovorin Irinotecan Gastroenterology Antimetabolite Disease-Free Survival Drug Administration Schedule Hepatic arterial infusion Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Infusions Intra-Arterial Infusions Intravenous Aged Chemotherapy business.industry Liver Neoplasms Hematology Middle Aged medicine.disease Combined Modality Therapy Surgery Oncology Fluorouracil Doxorubicin Camptothecin Female business Colorectal Neoplasms medicine.drug |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 14(10) |
| ISSN: | 0923-7534 |
| Popis: | Background: The purpose of this study was to evaluate the tolerance and efficacy of combining i.v. irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer. Patients and methods: Thirty-one patients were included in a phase II trial with i.v. irinotecan/5-FU/LV administered every 2 weeks, combined with HAI pirarubicin 60 mg/m 2 on day 1 every 4 weeks. In most cases HAI was administered via a percutaneous catheter. Results: The main grade 3/4 toxicity was neutropenia, encountered in 78% of the patients. When all patients were considered in the analysis, tumour response rate was 15 out of 31 [48%; 95% confidence interval (CI) 32% to 65%]. Liver resection was made possible in 11 patients (35%; 95% CI 21% to 53%). There were no toxic death. Median overall survival was 20.5 months, and median progression-free survival was 9.1 months. In patients with completely resected metastases, median overall survival was not reached and median progressionfree survival was 20.2 months. Conclusion: The multimodality approach used in the present study was well-tolerated and yielded dramatic responses. An aggressive approach combining i.v. and HAI chemotherapy deserves further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|